Clinical Trial Update: Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury [Phase 4]

View source ↗

Summary

A Phase 4 trial is comparing nafamostat mesylate to regional citrate anticoagulation for continuous renal replacement therapy in sepsis-associated acute kidney …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Sepsis

Drugs mentioned

• Nafamostat Mesylate (nafamostat)
• Regional citrate anticoagulation

Snippet

Sponsor: Jianfeng Xie | Conditions: Sepsis, Acute Kidney Injury | Phase 4 | Status: NOT_YET_RECRUITING